Relationships of in vitro sensitivities tested with nine drugs and two types of irradiation in chronic lymphocytic leukemia

Leukemia Research

Volumn 26, Issue 11, 2002, Pages 1035-1041

  Kivekäs, Ilkka ^a,b   Vilpo, Leena ^a,b   Vilpo, Juhani ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOSPORIN A; DOXORUBICIN; FLUDARABINE; LEUCINE; PREDNISOLONE; VERAPAMIL; VINCRISTINE;

ARTICLE; CELL HETEROGENEITY; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL; ULTRAVIOLET IRRADIATION;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL DIVISION; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0036842231     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00050-4     Document Type: Article

References (21)

1. Dalton W. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol. 34(Suppl 5):1997;3-8.
2. Bosanquet A.G., Bell P.B. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood. 87:1996;1962-1971.
3. Myllyperkiö M., Koski T., Vilpo L., Vilpo J. Gamma-irradiation-induced DNA single- and double-strand breaks and their repair in chronic lymphocytic leukemia of variable radiosensitivity. Hematol. Cell Therapy. 41:1999;95-103.
4. Myllyperkiö M., Koski T., Vilpo L., Vilpo J. Kinetics of excision repair of UV-induced DNA damage, measured using the comet assay. Mutat. Res. 448:1999;1-9.
5. Koski T., Aine R., Vilpo L., Vilpo J. Cyclosporin A-induced cell kill in vitro in various clinical-hematological types of B cell chronic lymphocytic leukemia. Leuk. Res. 24:2000;805-812.
6. Vilpo J., Koski T., Vilpo L. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia in vitro. Haematologica. 85:2000;806-813.
7. Vilpo J., Vilpo L. Selective toxicity of vincristine against chronic lymphocytic leukaemia in vitro. The Tampere CLL Group (letter). Lancet. 347:1996;1491-1492.
8. Vilpo J., Koski T., Vilpo L. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur. J. Haematol. 65:2000;1-9.
9. Koski T., Vilpo L., Vilpo J. Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia. Leuk. Res. 23:1999;277-279.
10. Koski T., Karhu R., Visakorpi T., Vilpo L., Knuutila S., Vilpo J. Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance. Eur. J. Haematol. 65:2000;32-39.
11. Begleiter A., Verburg L., Ashique A., Lee K., Israels L., Mowat M.et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia. 9:1995;1875-1881.
12. Bennett J., Catovsky D., Daniel M., Flandrin G., Galton D., Gralnick H.et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J. Clin. Pathol. 42:1989;567-584.
13. Vilpo J., Vilpo L., Hulkkonen J., Lankinen M., Kuusela P., Hurme M. Non-specific binding compromises the purification yields of leukemic B-cells in chronic lymphocytic leukemia: prevention by collagen coating. Eur. J. Haematol. 60:1998;65-67.
14. Kivekäs I, Hulkkonen J, Hurme M, Vilpo L, Vilpo J. CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia. Leuk Res 2002;26:443-446.
15. Silber R., Degar B., Costin D., Newcomb E.W., Mani M., Rosenberg C.R.et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood. 84:1994;3440-3446.
16. Hanson J.A., Bentley D.P., Bean E.A., Nute S.R., Moore J.L. In vitro chemosensitivity testing in chronic lymphocytic leukaemia patients. Leuk. Res. 15:1991;565-569.
17. Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J. Natl. Cancer Inst. 82:1990;1133-1140.
18. Cumber P.M., Jacobs A., Hoy T., Fisher J., Whittaker J.A., Tsuruo T.et al. Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia. Br. J. Haematol. 76:1990;226-230.
19. Shustik C., Groulx N., Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br. J. Haematol. 79:1991;50-56.
20. Michieli M., Raspadori D., Damiani D., Geromin A., Gallizia C., Michelutti A.et al. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 77:1991;460-465.
21. Sparrow R.L., Hall F.J., Siregar H., Van der Weyden M.B. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk. Res. 17:1993;941-947.